[go: up one dir, main page]

CR20130349A - COMPUESTOS SUSTITUIDOS DE N-(1H- INDAZOL-4-IL) IMIDAZO [1,2-a] PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III - Google Patents

COMPUESTOS SUSTITUIDOS DE N-(1H- INDAZOL-4-IL) IMIDAZO [1,2-a] PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III

Info

Publication number
CR20130349A
CR20130349A CR20130349A CR20130349A CR20130349A CR 20130349 A CR20130349 A CR 20130349A CR 20130349 A CR20130349 A CR 20130349A CR 20130349 A CR20130349 A CR 20130349A CR 20130349 A CR20130349 A CR 20130349A
Authority
CR
Costa Rica
Prior art keywords
type
kinosa
piridin
indazol
imidazo
Prior art date
Application number
CR20130349A
Other languages
English (en)
Inventor
Mark Laurence Boys
Robert Kirk Delisle
Erik James Hicken
April L Kennedy
David A Mareska
Fredrik P Marmsater
Mark C Munson
Brad Newhouse
Bryson Rast
James P Rizzi
Martha E Rodriguez
George T Topalov
Qian Zhao
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CR20130349A publication Critical patent/CR20130349A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

COMPUESTOS DE FÓRMULA I.-
CR20130349A 2010-12-13 2013-07-15 COMPUESTOS SUSTITUIDOS DE N-(1H- INDAZOL-4-IL) IMIDAZO [1,2-a] PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III CR20130349A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42254710P 2010-12-13 2010-12-13
PCT/US2011/064549 WO2012082689A1 (en) 2010-12-13 2011-12-13 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
CR20130349A true CR20130349A (es) 2013-08-09

Family

ID=45478484

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130349A CR20130349A (es) 2010-12-13 2013-07-15 COMPUESTOS SUSTITUIDOS DE N-(1H- INDAZOL-4-IL) IMIDAZO [1,2-a] PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III

Country Status (32)

Country Link
US (3) US9174981B2 (es)
EP (1) EP2651939B1 (es)
JP (3) JP5868996B2 (es)
KR (1) KR101974665B1 (es)
CN (3) CN105924437B (es)
AU (3) AU2011344001B2 (es)
BR (1) BR112013014854B1 (es)
CA (2) CA3027814A1 (es)
CL (1) CL2013001712A1 (es)
CO (1) CO6751248A2 (es)
CR (1) CR20130349A (es)
DK (1) DK2651939T3 (es)
ES (1) ES2540996T3 (es)
HR (1) HRP20150571T1 (es)
HU (1) HUE025416T2 (es)
IL (1) IL226911A (es)
ME (1) ME02172B (es)
MX (1) MX2013006763A (es)
MY (1) MY172110A (es)
NZ (1) NZ613235A (es)
PH (1) PH12013501221A1 (es)
PL (1) PL2651939T3 (es)
PT (1) PT2651939E (es)
RS (1) RS54070B1 (es)
RU (1) RU2591195C2 (es)
SG (1) SG191129A1 (es)
SI (1) SI2651939T1 (es)
SM (1) SMT201500165B (es)
TW (1) TWI527813B (es)
UA (1) UA112425C2 (es)
UY (1) UY33801A (es)
WO (1) WO2012082689A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102822170B (zh) * 2009-12-21 2014-12-10 阵列生物制药公司 作为cFMS抑制剂的取代的N-(1H-吲唑-4-基)咪唑并[1,2-a]吡啶-3-羧酰胺化合物
PT2651939E (pt) 2010-12-13 2015-08-04 Array Biopharma Inc Compostos n-(1h-indazol-4-il)imidazo[1,2-a]piridina-3- carboxamida substituídos enquanto inibidores de tirosina quinase de receptores de tipo iii
GB201315486D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CN104496891A (zh) * 2014-12-06 2015-04-08 哈尔滨工业大学 吡啶衍生物2-叔丁氧基-6-亚甲基氯吡啶的合成方法
CN104974078A (zh) * 2015-06-25 2015-10-14 黄荣辉 一种2-甲基-6-氯甲基吡啶盐酸盐的制备方法
US10836742B2 (en) 2015-08-11 2020-11-17 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
CN108290856A (zh) 2015-08-11 2018-07-17 尼奥迈德研究所 芳基-取代的二氢喹诺酮、它们的制备和它们作为药物的用途
KR102784592B1 (ko) 2015-08-12 2025-03-19 에피제네틱스, 인크. 치환된 벤즈이미다졸, 그의 제조법 및 제약으로서의 그의 용도
WO2017066876A1 (en) 2015-10-21 2017-04-27 Neomed Institute Substituted imidazopyridines, their preparation and their use as pharmaceuticals
US10889564B2 (en) 2015-11-02 2021-01-12 Genase Therapeutics B.V. Tetrahydroindazoles and medical uses thereof
CN105198799A (zh) * 2015-11-03 2015-12-30 江苏梦得电镀化学品有限公司 一种2-甲基-6-氯甲基吡啶盐酸盐的制备方法
US10519151B2 (en) 2016-01-28 2019-12-31 Neomed Institute Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
US10934285B2 (en) * 2016-06-14 2021-03-02 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
CN106187899B (zh) * 2016-06-28 2019-07-16 绍兴文理学院 一种氟代氮杂芳烃的合成方法
CN109790079B (zh) * 2016-07-29 2022-06-03 香港科技大学 有机锌试剂与杂环(拟)卤化物的C(sp3)-C(sp2)交叉偶联反应
AU2017355603A1 (en) 2016-11-04 2019-06-20 Auckland Uniservices Limited Tricyclic heterocyclic derivatives and uses thereof
KR102425785B1 (ko) * 2016-11-28 2022-07-28 에자이 알앤드디 매니지먼트 가부시키가이샤 인다졸 유도체의 염 및 이의 결정
WO2018213665A1 (en) 2017-05-19 2018-11-22 Syndax Pharmaceuticals, Inc. Combination therapies
SI3658552T1 (sl) 2017-07-28 2023-11-30 Yuhan Corporation Postopek za pripravo N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidin-2-il )amino)-4-metoksi-2-morfolinofenil)akrilamida z reagiranjem ustreznega amina s 3-halo-propionil kloridom
EP3765459A1 (en) 2018-03-13 2021-01-20 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
CN111410654B (zh) * 2019-01-19 2022-05-17 江苏新元素医药科技有限公司 3-溴-5-(2-乙基咪唑并[1,2-a]吡啶-3-羰基)-2-羟基苯甲腈的合成
TWI841671B (zh) 2019-01-24 2024-05-11 日商第一三共股份有限公司 具有取代基之脲化合物
TWI759829B (zh) 2019-08-23 2022-04-01 財團法人生物技術開發中心 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
JP7695232B2 (ja) 2019-09-18 2025-06-18 武田薬品工業株式会社 ヘテロアリール血漿カリクレインインヒビター
US11787796B2 (en) 2019-09-18 2023-10-17 Takeda Pharmaceutical Company Limited Plasma Kallikrein inhibitors and uses thereof
WO2025146196A1 (zh) * 2024-01-04 2025-07-10 上海翰森生物医药科技有限公司 多环类衍生物抑制剂、其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
EP1511742B1 (en) 2002-05-23 2010-02-03 Cytopia Research Pty Ltd Kinase inhibitors
JP5442449B2 (ja) * 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
KR101538179B1 (ko) * 2007-04-03 2015-07-20 어레이 바이오파마 인크. 수용체 티로신 키나제 억제제로서의 이미다조[1,2-a]피리딘 화합물
FR2925901B1 (fr) 2008-01-02 2011-03-04 Sanofi Aventis DERIVES DE N-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
WO2009147189A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
TW201105669A (en) * 2009-07-30 2011-02-16 Irm Llc Compounds and compositions as Syk kinase inhibitors
CN102822170B (zh) * 2009-12-21 2014-12-10 阵列生物制药公司 作为cFMS抑制剂的取代的N-(1H-吲唑-4-基)咪唑并[1,2-a]吡啶-3-羧酰胺化合物
PT2651939E (pt) * 2010-12-13 2015-08-04 Array Biopharma Inc Compostos n-(1h-indazol-4-il)imidazo[1,2-a]piridina-3- carboxamida substituídos enquanto inibidores de tirosina quinase de receptores de tipo iii
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
CN102250246A (zh) * 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用

Also Published As

Publication number Publication date
PL2651939T3 (pl) 2015-10-30
CL2013001712A1 (es) 2013-12-06
CA3027814A1 (en) 2012-06-21
SI2651939T1 (sl) 2015-07-31
CO6751248A2 (es) 2013-09-16
ES2540996T3 (es) 2015-07-15
SMT201500165B (it) 2015-09-07
AU2018201903B2 (en) 2019-09-19
US20130274244A1 (en) 2013-10-17
US20160002232A1 (en) 2016-01-07
CN109608449A (zh) 2019-04-12
KR20140014109A (ko) 2014-02-05
CA2821712C (en) 2019-02-12
US9174981B2 (en) 2015-11-03
RU2013132758A (ru) 2015-01-20
MX2013006763A (es) 2014-01-08
TW201305156A (zh) 2013-02-01
MY172110A (en) 2019-11-14
HUE025416T2 (en) 2016-02-29
US9809590B2 (en) 2017-11-07
PH12013501221A1 (en) 2022-03-30
BR112013014854B1 (pt) 2020-12-08
JP5868996B2 (ja) 2016-02-24
PT2651939E (pt) 2015-08-04
RS54070B1 (sr) 2015-10-30
KR101974665B1 (ko) 2019-05-02
US10669269B2 (en) 2020-06-02
AU2018201903A1 (en) 2018-04-12
CN103347882B (zh) 2016-05-11
NZ613235A (en) 2015-04-24
WO2012082689A1 (en) 2012-06-21
JP2013545808A (ja) 2013-12-26
HK1190709A1 (en) 2014-07-11
JP2016040303A (ja) 2016-03-24
US20180086758A1 (en) 2018-03-29
BR112013014854A8 (pt) 2018-03-27
IL226911A (en) 2016-09-29
AU2016222468A1 (en) 2016-09-22
RU2591195C2 (ru) 2016-07-10
JP2018065835A (ja) 2018-04-26
HRP20150571T1 (xx) 2015-07-03
ME02172B (me) 2015-10-20
AU2011344001B2 (en) 2016-06-30
DK2651939T3 (en) 2015-06-01
UY33801A (es) 2013-06-28
TWI527813B (zh) 2016-04-01
EP2651939A1 (en) 2013-10-23
BR112013014854A2 (pt) 2016-10-18
UA112425C2 (uk) 2016-09-12
EP2651939B1 (en) 2015-04-08
CN105924437B (zh) 2018-11-30
SG191129A1 (en) 2013-07-31
CA2821712A1 (en) 2012-06-21
AU2016222468B2 (en) 2017-12-21
CN105924437A (zh) 2016-09-07
CN103347882A (zh) 2013-10-09

Similar Documents

Publication Publication Date Title
CR20130349A (es) COMPUESTOS SUSTITUIDOS DE N-(1H- INDAZOL-4-IL) IMIDAZO [1,2-a] PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III
CR20120635A (es) Compuestos heterocìclicos de nitrògeno ùtiles como inhibidores de pde10
CY1119345T1 (el) Μακροκυκλικες ενωσεις ως αναστολεις κινασης trk
UY33888A (es) Derivados de (1,2,4) triazolo [4,3-a) quinoxalina como inhibidores de fosfodiesterasas
CR20120641A (es) Compuestos macrocìclicos como inhibidores de quinasa trk
UY34301A (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit
CR20120295A (es) Triazolopiridinas
CR20120637A (es) Triazolopiridinas sustituidas
CO6831982A2 (es) Pirazolo[4,3-d]pirimidinas útiles como inhibidores de cinasas
CO6491116A2 (es) Derivados de 5-fluoropirimidinona
CR20130045A (es) Compuestos terapéuticos
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
CR20120297A (es) Espironucleósidos uracílicos oxetánicos
CR20120565A (es) Indoles
UY34300A (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
CR20120121A (es) Compuestos de benzoxazepina como inhibidores de la pi3k y métodos de uso
CO6592042A2 (es) Derivados de n3-sustituido -n1-sulfonil-5-fluorpirimidinona
AU2014270524A8 (en) 2-phenylimidazo [1,2-a]pyrimidines as imaging agents
UY34445A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
AU2012213775A8 (en) 7-azaindole derivatives
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
UY34352A (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
CU24045B1 (es) Aril piridinas como inhibidoras de sintasa de aldosterona
CR20130118A (es) DERIVADOS DE PIRAZINA COMO BLOQUEADORES DE ENaC